Log in to search using one of your social media accounts:

 

Expanded Access Use of Tucatinib for HER2+ Metastatic Breast Cancer

Condition:   Intervention:   Drug: Tucatinib Sponsor:   Cascadian Therapeutics Inc. Available
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

Conclusions: Patients who have had an axillary lymph node dissection and limited node-positive disease may be candidates for treatment with APBI. Further research is ultimately needed to better define specific criteria for APBI in node-positive patients.
Source: American Journal of Clinical Oncology - Category: Cancer & Oncology Tags: Original Articles: Breast Source Type: research
CONCLUSION: Postmenopausal women with HR+/HER2- mBC who have previously failed an NSAI and received palbociclib+fulvestrant, everolimus+AI or everolimus+fulvestrant had longer PFS compared to those who received fulvestrant or AI alone. PMID: 29781326 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research
Condition:   Breast Neoplasms Interventions:   Drug: Denosumab 120 mg;   Drug: Denosumab 60 mg Sponsors:   Borstkanker Onderzoek Groep;   Amgen Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
The standard of care for HER2-positive breast cancer is trastuzumab (Herceptin) for a year; but could half that be enough?Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
M árcio Debiasi, Carisi A. Polanczyk, Patrícia Ziegelmann, Carlos Barrios, Hongyuan Cao, James J. Dignam, Paul Goss, Brittany Bychkovsky, Dianne M. Finkelstein, Rodrigo S. Guindalini, Paulo Filho, Caroline Albuquerque, Tomás Reinert, Evandro de Azambuja, Olufunmilayo Olopade
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Contributors : Luciano Castiello ; Eleonora Aric ò ; Paola Sestili ; Filippo Belardelli ; Enrico Proietti ; Giovanna Schiavoni ; Domenica Monque ; Antonella Sistigu ; Rosanna Dattilo ; Fiorella Ciaffoni ; Mauro Biffoni ; Maria Ferrantini ; Manuela Iezzi ; Federica Moschella ; Alessi Lamolinara ; Ann Zeuner ; Anna M Pacca ; Daniele MacchiaSeries Type : Expression profiling by arrayOrganism : Mus musculusType I Interferons (IFN-I) are anti-viral and immuno-modulating cytokines involved in many steps across tumor initiation and progression. IFN-I act directly on tumor cells inhibiting cell growth and indirectly by acti...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by array Mus musculus Source Type: research
Conditions:   HER2-positive Breast Cancer;   Breast Cancer;   Breast Cancer Stage;   Recurrent Breast Cancer;   Metastatic Breast Cancer;   HER2 Positive Breast Carcinoma Interventions:   Drug: Palbociclib;   Drug: T-DM1 Sponsors:   University of Arizona;   Pfizer Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Recent survival results lead some to question the optimal sequence for trastuzumab emtansine in metastatic breast cancer.Chinese Clinical Oncology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
The American Joint Committee on Cancer staging system has evolved in response to improved imaging, refined surgical techniques, enhanced pathologic evaluation, and greater understanding of tumor biology. The 8th edition has introduced clinical and pathologic prognostic stages for breast cancer that incorporate biologic variables (grade, estrogen/progesterone receptor status, HER2 status, multigene panels) with TNM categories that define the anatomic stage. The prognostic staging system facilitates more refined stratification than the anatomic stage with respect to survival and is an important advance that maintains the cli...
Source: Surgical Clinics of North America - Category: Surgery Authors: Source Type: research
Authors: Meirson T, Genna A, Lukic N, Makhnii T, Alter J, Sharma VP, Wang Y, Samson AO, Condeelis JS, Gil-Henn H Abstract Metastatic dissemination of cancer cells from the primary tumor and their spread to distant sites in the body is the leading cause of mortality in breast cancer patients. While researchers have identified treatments that shrink or slow metastatic tumors, no treatment that permanently eradicates metastasis exists at present. Here, we show that the ABL kinase inhibitors imatinib, nilotinib, and GNF-5 impede invadopodium precursor formation and cortactin-phosphorylation dependent invadopodium matur...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | HER2